PHARMACOLOGY CONFERENCE Andal, Ang, J, Ang JM, Ang, K., Aningalan, A.
-
Upload
eugenia-hill -
Category
Documents
-
view
252 -
download
3
Transcript of PHARMACOLOGY CONFERENCE Andal, Ang, J, Ang JM, Ang, K., Aningalan, A.
PHARMACOLOGY CONFERENCE
Andal, Ang, J, Ang JM, Ang, K., Aningalan, A.
General Data
• C.R.• 1 y/o• Male
Chief Complaint:
Swelling of the L arm
History of Present Illness• 2 x 2 cm solitary plaque on the L
forearm; erythematous, smooth, raised border; tender, warm, firm to touch
• Lesion increased in size: 4x 4cm • consult at a local clinic
– Prescribed to take Cloxacillin (unrecalled dose), 3mL every 6 hours for 7 days
• The lesion decreased in size to about 3 x 3cm, soft to touch
3 weeks PTA
2 weeks PTA
History of Present Illness• Lesion became a 3x3cm fluctuant
abscess, tender, well defined border• Consult at another local clinic
– I & D: discharge was noted to be bloody and with pus, approximately 10 mL
– Clindamycin was discontinued, and was prescribed Co-amoxiclav (Augmentin) (unrecalled dose) 5mL every 8 hours
• Mother did not give the said medication because she believed that the incision and drainage was enough to heal the lesion
9 days PTA
History of Present Illness• 4 x 4 cm plaque of the same character
appeared adjacent to the previous lesion.• lesion evolved into an 4x4 cm abscess,
with erythmatous, well-defined margin, tender to touch
• Co-amoxiclav(unrecalled dose) 5 mL every 8 hours was given– noted appearance of maculopapular
rashes on the neck, back, abdomen and legs so the medication
– discontinued after 2 days.
7 days PTA
3 days PTA
History of Present Illness• Undocumented fever (patient
was warm to touch)• Ibuprofen (Dolan FP)
100mg/5mL suspension 3 mL every 4 hours was given
• Persistence of symptoms
1 day PTA
ADMISSION
Review of Systems(-) wt loss, anorexia, weakness, (-) blurring of vision, eye redness, eye itchiness, Iacrimation(-) deafness, tinnitus, aural discharge(-) anosmia, epistaxis, sinusitis, nasal discharge(-) bleeding gums, oral sores, tonsillitis (-) neck mass, neck stiffness, limitation of motion(-) breast masses, discharge, trauma
Review of Systems(-) dyspnea, alar flaring, cough, hemoptysis(-) easy fatigability, chest pain,edema(-) phlebitis, varicosities, claudication(-) dyshpagia, nausea, vomiting, hematemesis,
melena, hematochezia, diarrhea, constipation(-) urinary frequency, urgency, hesitancy,
dysuria, hematuria, nocturia(-) joint stiffness, joint pain, muscle pain, cramps
Review of Systems
(-) heat-cold intolerance, polydipsia, polyphagia, polyuria
(-) headache, speech disturbance, seizures(-) anxiety, depression, confusion
Personal History
Gestational History, Birth and Neonatal History
• born to a 29-year old, G3P2, housewife, living with a 54-year old government employee.
• regular prenatal check-up • took Folic Acid and FeSO4 • 2 shots of Tetanus toxoid. • no illicit drug use, alcoholic intake, exposure to viral
exanthems, teratogenic drugs, cigarette smoke and radiation.
Personal History
• Gestational History, Birth and Neonatal History• No illnesses during the pregnancy• Patient was born live, term, singleton, male, via
CS secondary to cephalopelvic disproportion in Jose Reyes MM
• unrecalled birth weight and birth length. • good cry at delivery, spontaneous respiration,
and not meconium-stained.
Personal History
Feeding History• exclusively breast fed during the first 3 months and was
then shifted to Bonna milk• shifted to Bonamil at 6 months and then to Nido fortified at
1 year• Complementary food was introduced at 6 months, starting
with mashed fruits and vegetables • Currently takes Nido fortified; 1:1 dilution, 8-9
feedings/day, 7 oz/feeding• Patient is not a picky eater; usually eats fruits, vegetables,
chicken liver, fish and rice
24-Hour Food RecallCHO CHON Fats Total Calories
Breakfast Oatmeal (1/2 cup) 11.5 1 61LunchMilk biscuit (2 pcs.) 23 2 100MeriendaKalamansi juice (4oz.)Ice cream (1/3 cup)
1023
2 40100
DinnerMilk (9 bottles – 8oz. each)
84 56 70 1190
ACI 1490RENI 1070% Intake 139 %
Developmental History:
Patient is at par with age Walks alone with one hand held Stands alone Begins to feed with fingers Kisses on request Releases object on request Obeys commands with gestures
Past Medical History:
• No previous hospitalizations/major illnesses• No previous surgeries• No previous blood transfusions
Immunizations:
• incomplete immunization; unrecalled dates• BCG1
• DPT123
• OPV123
• HepB 123
• Measles• HiB1
Family History:
• (+) Diabetes Mellitus – maternal great grandmother, maternal aunt
• (+) Hypertension – maternal grandmother• (+) asthma – maternal grandfather • (-) PTB, Cancer, Hematologic diseases, Goiter
Family Profile
Family
MemberAge Relationship Ed. Attainment Occupation Health
StatusCR 55 Father College graduate –
AB HistoryGovernment
employeehealthy
IR 30 Mother College undergrad Housewife healthy
AR 10 Sister Grade 4 Student healthy
ER 9 Brother Grade 3 Student healthy
RR 46 Uncle High School graduate
Unemployed healthy
Personal, Socioeconomic and Environmental History
• lives with her parents, 2 siblings and uncle • well-spaced, well-ventilated and well-lit • two-storey house made of cement• Drinking water is mineral water• Garbage is burned every day• Does not live near a factory and has no pets. • Exposed to cigarette smoke (Uncle)
Physical ExaminationGeneral: Alert, awake, irritable, not in cardiorespiratory
distress, well-nourished, well-hydratedVital Signs: CR:105 bpm, regular RR:25 cpm, regular T:36.5°C
Ht: 78 cm (z-score: 0, normal), Wt: 14 kg (z-score: 3, obese),
BMI= 23.3 (z-score: above 3, obese)Skin: Warm, moist skin, (+) maculopapular rash on bilateral
thigh, palms and solesHead: No gross head deformities, HC = 53 cm (z-score: +3), no
lesions on the head, equally distributed fine black hair, closed fontanels
Physical ExaminationPink palpebral conjunctivae, pupils 2-3 mm ERTL, anicteric
scleraeNo tragal tenderness, no ear discharge, non-hyperemic
external auditory canal, intact tympanic membrane, with retained cerumen
Midline septum, no nasal discharge, turbinates not congested, no alar flaring
Moist buccal mucosa, no oral ulcers, nonhyperemic posterior pharyngeal wall, tosils not enlarged
Supple neck, no palpable cervical lymph nodes, no masses, thyroid gland not enlarged
Physical Examination
Heart: Adynamic precordium, AB at 4th LICS MCL, S1>S2 at apex, S2>S1 at base, no heaves, no lifts, no thrills, no murmurs
Lungs: Symmetrical chest expansion, no retractions, no use of accessory muscles, clear breath sounds
Abdomen: Globular, soft, with normoactive bowel sounds, no tenderness, no masses
External Genitalia: Grossly male genitalia
Physical Examination
Extremities: No limitations in range of motion, no joint swelling or tenderness; pulses full and equal, no cyanosis, no clubbing, (+) warm, tender, erythematous, fluctuant, 4x4cm mass on the left forearm with well-defined border.
Neurologic Exam on Admission
• Alert, awake, aware of surroundings• No asymmetry, no gross deformities, no bulging of fontanels, no
hydrocephalus• Spontaneous muscle movements, no involuntary movements,
no tremors• Cranial Nerves: CN2- visual tracking, blinks with bright lightCN3, 4, 6- no ptosis, pupils 2-3 mm ERTL; CN5- blinks upon gentle
air blowing; CN7- no facial asymmetry; CN8- turns head to stimulus; CN9, 10- normal suck and swallowing; CN 11- symmetry of SCM muscle bulk
• (-) Involuntary movements• (-) Nuchal rigidity, (-) Babinski
Salient Features• 1 y/o M• (+) warm, tender, erythematous, fluctuant,
4x4cm mass on the left forearm with well-defined border
• (+) maculopapular rash on bilateral thigh, palms and soles
• Irritable• Undocumented fever
Symptom, signs and laboratory finding found in the least number of disease
• Fluctuant Mass
Differential Diagnosis• V—Vascular conditions of the skin like postphlebitic ulcers that cause a
discharge• I—Inflammatory conditions of a noninfectious nature like erythema
multiforme, pyoderma gangrenosum, and pemphigus that produce weeping. Specific infections are listed above.
• T—Traumatic conditions such as third-degree burns• A—Autoimmune and allergic disorders associated with weeping vesicles
and ulcers, such as periarteritis nodosa and contact dermatitis• M—Malformations such as bronchial clefts and urachal sinus tracts• I—Intoxicating lesions such as a vesicular or bullous drug eruption• N—Neoplasms such as basal cell carcinoma and mycosis fungoides that
produce weeping ulcers
Infectious Disorders (Specific Agent)
• Immune deficiency, acquired (AIDS/HIV)
• Infestations/fleas/mites/lice • Sporotrichosis • Cryptococcosis • Glanders (malleomyces mallei) • Loiasis/Loa loa infestation • American
leishmaniasis/cutaneous • Angiomatosis, bacterial
Bartonellosis • Blastomycosis • Cytomegalic virus, congenital
• Glanders abscess • Histoplasmosis, African • Milkers nodules• Mycobacterium
marinum/granuloma skin • Skin infections/Pyoderma • Toxoplasmosis, congental • Whipples disease • Chromoblastomycosis/
chromomycosis • Farcy/Cutaneous Glanders • Cutaneous fungal infection
Infected organ, Abscesses
• Adenitis/lymph node • Furunculosis • Abscess, subcutaneous • Carbuncle • Pyoderma granuloma (vegetans)
Granulomatous, Inflammatory Disorders
• Panniculitis
Neoplastic Disorders
• Hemangioma• Lipoma• Leukemia, acute • Melanoma, malignant • Hodgkin's disease • Kaposi Sarcoma
Allergic, Collagen, Auto-Immune Disorders
• Juvenile rheumatoid arthritis/Stills d • Erythema nodosum • Juvenile chronic arthritis (rheumatoid) • Neonatal subcutaneous fat necrosis • Panniculitis, nodular nonsuppurative • Polyarteritis nodosa • Rheumatoid arteritis/vasculitis • Rheumatoid nodule • Polyarteritis nodosa, infantile
Metabolic, Storage Disorders
• Gout • Tophi/Gouty tophi • Pseudogout syndrome • Amyloidosis, primary nonhereditary
Congenital, Developmental Disorders
• Arteriovenous malformations• Cavernous lymphangioma• Angioma/cutaneous• Dermoid cyst
Hereditary, Familial, Genetic Disorders
• Ehlers-Danlos syndrome• Gardner syndrome• Neurofibromatosis• Tuberous Sclerosis• Lipodystrophy, generalized
Anatomic, Foreign Body, Structural Disorders
• Sebaceous cyst• Soft tissue foreign body/subcutaneous • Keloid• Joint ganglion
Approach
• Smear and culture • skin biopsy • Serologic tests • cultures on special (fungi and parasites)
Others
• CBC (systemic infection)• Sedimentation rate (systemic infection, collagen
disease)• Tuberculin test• VDRL test (primary or secondary syphilis)• X-ray of area involved (abscess, osteomyelitis)• ANA analysis (collagen disease)• Skin test and serology for fungi• Biopsy• Muscle biopsy (collagen disease, trichinosis)
COURSE IN THE WARD
1ST Hospital Day• IVF: D5 IMB 500mL to run at 12-13 gtts/min• Request for:
– CBC with platelet– Gram stain of wound discharge– Culture and sensitivity of wound discharge
• Medications:– Clindamycin 150mg/slow IV infusion (32.1mg/kg/day) over 30
mins. now then every 8 hrs. ANST– Amikacin 100mg/slow IV push over (21.4mg/kg/day) 30 mins.
every 8 hrs.– Paracetamol 250mg/5mL, 4 mL every 4 hours for Temp. > 38.5°C or
for pain (14 mg/kg/dose )– Refer to Pediatric Surgery for further evaluation and management
1st Hospital Day
• Incision and Drainage of Abscess– 20cc purulent discharge– Specimen sent for GS/CS
• For daily COD
Complete Blood Count
Hgb 110
RBC 4.11
Hct 0.33
MCV 79.90
MCH 26.80
MCHC 33.50
RDW 14.00
MPV 6.20
Platelet 281
WBC 12.10
Neutrophils 0.54
Lymphocytes 0.41
Monocytes 0.03
Eosinophils 0.02
Microbiology Examination
Gram (+) Cocci in Pairs Few
Pus Cells ++++
2nd Hospital Day• D1-2 – Clindamycin 150mg/slow IV infusion (32.1mg/kg/day)
over 30 mins. now then every 8 hrs. ANST– Amikacin 100mg/slow IV push over (21.4mg/kg/day) 30
mins. every 8 hrs.• Decreased to D5 IMB 500mL to run at 9-10 gtts/min• Patient was transferred to malward• IVF to consume• Increase oral fluid intake
Culture and Sensitivity: Wound Discharge
Staphylococcus aureus Heavy Growth
*MRSA Positive
Sensitive to:
Azithromycin Chloramphenicol ClindamycinErythromycin Gentamycin Co-trimoxazole
Vancomycin
Resistant to:
Penicillin
5th Hospital Day
• D5-6– Clindamycin 150mg/slow IV infusion
(32.1mg/kg/day) over 30 mins. now then every 8 hrs. ANST
– Amikacin 100mg/slow IV push over (21.4mg/kg/day) 30 mins. every 8 hrs.
• 0.65% NaCl Nasal drops 2-3 gtts/nostril then suction Q6
14th Hospital Day
• Day 14– Clindamycin 150mg/slow IV infusion (32.1mg/kg/day) over 30 mins.
now then every 8 hrs. ANST– Amikacin 100mg/slow IV push over (21.4mg/kg/day) 30 mins. every 8
hrs.• Disharged
– Final Diagnosis: Abscess secondary to MRSA – Take Home Medications:
• Co-trimoxazole 400mg 180mg/5mL, 4mL Q12 to complete for 2 weeks• Mupirocin ointment, apply on affected area TID
– Anticipatory Guidance– Immunization update– For follow up at OPD on Oct 10, 2010
Antibacterial activity of honey against community-associated methicillin-resistant Staphylococcus aureus
(CA-MRSA)Maedaab et. Al
Complementary Therapies in Clinical Practice (2008) 14, 77–82
Introduction
• There has been increasing reports of community acquired MRSA amongst healthy individuals, who have no hospital association
• Predominant presentation is associated with skin and soft tissue infections, particularly folliculitis, pustular lesions and abscesses.
• Risk factors for its acquisition include close physical contact, abrasion injuries and activities associated with poor communal hygiene (e.g. sharing towels).
Introduction
• Although honey has historically been known to have antimicrobial activity, to date, no reports have examined such activity against CA-MRSA.
• Previous literature have indicated honey as an effective treatment of HA-MRSA-related wound infection
• The aim of this small study to examine the potential antimicrobial activity of natural honey against a collection of CA-MRSA organisms.
Materials and Methods
• Natural honey samples (n ¼ 3; approx. 0.5 kg) were obtained from amateur bee-keepers in Northern Ireland, from the Mourne Mountains??
• Commercial French honey from the Suisse Normande was also included as a comparator honey.
• Honey was sterilized with gamma irradiation using cobalt-60 at an environmental temperature of 41oC
• 6 CA-MRSA isolates were included, including CA-MRSA ST35, 5134, 4388, 4266, 4526 and 5090
• Isolates were initially cultured on CBA for 24 h at 37.1oC
Materials and Methods• CA-MRSA inocula were thoroughly mixed into each honey and the honey was stored in the
dark for 24 h at ambient room temperature (approx. 18–200C). • Timepoints, t ¼ 0, 4, 8 and 24 h, • quantitative counts expressed as log10 cfu/g honey.• Following this, and in order to confirm when no CAMRSA• remained culturable, each CA-MRSA inocula/• honey combination underwent a non-selective• enrichment in nutrient broth (Oxoid CM1) (225 ml)• at 37 1C for 24 h, followed by plating of 100 ml• enrichment broth on CBA which was incubated at• 37 1C for 24 h. Any resulting colonies were confirmed• as MRSA by conventional phenotypic assays.• Appropriate controls were established which included• examining the persistence of each CA-MRSA• strain in 0.1% PS, as detailed above, in the absence• of honey.
Statistical Analysis
• Student t-test• probability value = p:0.05 (5%) ; significant
Results
Discussion• Recent emergence of CA-MRSA within the community, in
combination with multiresistance and evolving antibiotic resistance, respectively, merits an examination of alternative treatment regimens for these organisms making the current study timely and of interest to healthcare practitioners involved with in wound management.
• Previously, a small number of case studies have examined the antimicrobial activity of honey against MRSA organisms. Although these reports describe Manuka honey, as an active component in the resolution of wounds, no in vitro susceptibility data were presented to demonstrate the in vitro activity of the honey preparations against the MRSA isolated in situ
Discussion• Gamma-irradiated honey was employed – To perform the bacteriological analyses in pure
culture, using non-selective media– food-grade honey produced for human consumption,
although a shelf-stable product, is not a sterile product
• Analyses of these honey products demonstrated the presence of various Bacillus spp. In this study, seven samples of honey and related were examined microbiologically and were demonstrated to have total viable counts (TVC) ranging from 100 to 1700 cfu/g
Discussion
• Most frequently identified species were:– Bacillus pumilus– B. licheniformis– B. subtilis– B. fusiformis
• Practitioners should consider the employment of honey preparations that have been sterilised employing g-irradiation
Conclusion
• In vitro, natural products of honey had an antimicrobial activity against the CA-MRSA organisms tested.
• Further studies are now required to demonstrate the mechanism and components of such activity and whether this antimicrobial activity has any clinical application for the treatment of CA-MRSA skin and soft tissue infections.